
Opinion|Videos|April 3, 2025
Communication of Treatment Options for High-Risk NMIBC
Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you communicate various options for NMIBC with patients and healthcare professionals?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
5













